Computational approaches: atom-based 3D-QSAR, molecular docking, ADME-Tox, MD simulation and DFT to find novel multi-targeted anti-tubercular agents.

Computational approaches: atom-based 3D-QSAR, molecular docking, ADME-Tox, MD simulation and DFT to find novel multi-targeted anti-tubercular agents.

Publication date: Feb 13, 2025

Tuberculosis (TB) has become the biggest threat to human society because of the rapid rise in resistance to the causative bacteria Mycobacterium tuberculosis (MTB) against the available anti-tubercular drugs. There is an urgent need to design new multi-targeted anti-tubercular agents to overcome the resistance species of MTB through computational design tools. With this aim in mind, we performed a combination of atom-based three-dimensional quantitative structure-activity relationship (3D-QSAR), six-point pharmacophore (AHHRRR), and molecular docking analysis on a series of fifty-eight anti-tubercular agents. The created QSAR model had a R value of 0. 9521, a Q value of 0. 8589, and a Pearson r-factor of 0. 8988, all of which are statistically significant. This means that the model was effective at making predictions. We performed the molecular docking study for the data set of compounds with the two important anti-tubercular target proteins, Enoyl acyl carrier protein reductase (InhA) (PDBID: 2NSD) and Decaprenyl phosphoryl-β-D-Ribose 20-epimerase (DprE1) (PDBID: 4FDO). We used the similarity search principle to do virtual screening on 237 compounds from the PubChem database in order to find strong anti-tubercular agents that act against multiple targets. The screened compound, MK3, showed the highest docking score of -9. 2 and -8. 3 kJ/mol towards both the target proteins InhA and DprE1, which were picked for a 100 ns molecular-dynamic simulation study using GROMACS. The data showed that the compound MK3 was thermodynamically stable and effectively bound to both target proteins in their active binding pockets without much movement. The analysis of the highest occupied molecular orbital (HOMO), lowest unoccupied molecular orbital (LUMO), and energy gap predicts the molecular reactivity and stability of the identified molecule. Based on the result of the above studies, the proposed compound MK3 can be successfully used for the development of a novel multi-targeted anti-tubercular agent with high binding affinity and favourable ADME-T properties.

Open Access PDF

Concepts Keywords
3kj ADME-T
Mycobacterium Atom based 3D-QSAR
Orbital DFT
Tb DprE1 inhibitor
Thermodynamically InhA inhibitor
Molecular docking
Molecular dynamic simulation

Semantics

Type Source Name
disease MESH Tuberculosis
pathway KEGG Tuberculosis
disease IDO bacteria
disease MESH respiratory infections
disease MESH COVID 19 pandemic
pathway REACTOME Reproduction
disease MESH infection
disease MESH death
disease MESH morbidities
disease IDO quality
drug DRUGBANK Coenzyme M
drug DRUGBANK Isoniazid
drug DRUGBANK Ethionamide
disease IDO production
pathway REACTOME Fatty acids
pathway KEGG Fatty acid elongation
disease IDO process
disease IDO organism
drug DRUGBANK D-Proline
drug DRUGBANK Valproic Acid
drug DRUGBANK Nonoxynol-9
disease MESH aids
disease IDO assay
disease IDO entity
drug DRUGBANK Trestolone
drug DRUGBANK Esomeprazole
drug DRUGBANK NADH
drug DRUGBANK Water
disease IDO site
disease IDO algorithm
drug DRUGBANK Zinc
disease IDO protein
pathway REACTOME Metabolism
drug DRUGBANK Compound 18
drug DRUGBANK Activated charcoal
disease MESH drug induced liver injury
drug DRUGBANK Methyl isocyanate
drug DRUGBANK Rifampicin
drug DRUGBANK Ranitidine
drug DRUGBANK Hyaluronic acid
disease MESH colon adenocarcinoma
pathway REACTOME Intestinal absorption
drug DRUGBANK Amino acids
drug DRUGBANK (S)-Des-Me-Ampa
disease MESH coinfection
drug DRUGBANK Diethylstilbestrol
disease MESH cancer
drug DRUGBANK Coenzyme A
drug DRUGBANK Coumarin
disease MESH rheumatoid arthritis
pathway KEGG Rheumatoid arthritis
disease MESH cytokine storm
drug DRUGBANK Diosmin
drug DRUGBANK Risedronate
drug DRUGBANK Dolutegravir
disease MESH malaria
pathway KEGG Malaria
disease MESH coronavirus infection
drug DRUGBANK Efavirenz
drug DRUGBANK Benzimidazole
drug DRUGBANK BENZOTHIAZOLE
drug DRUGBANK Indoleacetic acid

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *